Garret A. Fitzgerald

Dr. Garret FitzGerald is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he directs the Institute for Translational Medicine and Therapeutics. Previously, he chaired the Department of Systems Pharmacology and Translational Therapeutics for more than 20 years. Dr. FitzGerald’s research has been characterized by an integrative approach to elucidating the mechanisms of drug action, drawing on work in cells, model organisms and humans. His work contributed fundamentally to the development of low-dose aspirin for cardioprotection. FitzGerald’s group was the first to predict and then mechanistically explain the cardiovascular hazard from NSAIDs. He has also discovered many products of lipid peroxidation and established their utility as indices of oxidant stress in vivo. His laboratory was the first to discover a molecular clock in the cardiovascular system and has studied the importance of peripheral clocks in aging and in the regulation of cardiovascular and metabolic function. Dr. FitzGerald has received the Boyle, Coakley, Harvey and St. Patrick’s Day medals, the Lucian, Scheele, Spector and Hunter Awards and the Cameron, Taylor, Herz, Lefoulan Delalande, and Schottenstein Prizes. He is a member of the National Academy of Medicine, an honorary member of the Royal Irish Academy and the UK Academy of Medicine, a member of the Leopoldina and of the Accademia dei Lyncei, a Fellow of the American Academy of the Arts and Sciences and of the Royal Society. He holds honorary degrees from UCD and RCSI in Dublin, Frankfurt, Edinburgh and King’s College, London.